Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Maxim Group from $60.00 to $110.00. They now have a "buy" rating on the stock.
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at HC Wainwright from $60.00 to $100.00. They now have a "buy" rating on the stock.
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds